stockrow
Friday 6 November 2026
Export CALC’s income statement to Excel — free account
CalciMedica Inc.
CALC Healthcare Biotechnology
- EPS
- −12.5%
- Free cash flow
- +31.4%
- Total debt
- +8.24%
Quarter to June 2026, against a year earlier
1.36
0.06
+4.62%
Follow CALC
Alert me
CalciMedica Inc. (CALC) P/E ratio
CalciMedica Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CALC CalciMedica Inc. | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)